What is a Kedcyla 160mg Injection?

Kedcyla 160mg Injection is a prescription medication primarily used to treat HER2-positive breast cancer, particularly in cases where the cancer has spread to other parts of the body or has not responded to previous treatments. The active ingredient in Kedcyla is ado-trastuzumab emtansine, which combines the targeting capability of trastuzumab (an antibody that binds to HER2 receptors) with the cytotoxic effects of emtansine, a chemotherapy agent that destroys cancer cells.

Can I Buy Kedcyla 160mg Injection Online in Pakistan?

Yes, you can buy Kedcyla 160mg Injection from Jasmeds, which is a reliable provider of wellness medicines in Pakistan offering 24/7 delivery service.

What Should You Do If You Take an Overdose of Kedcyla 160mg Injection?

In the event of an overdose of Kadcyla (ado-trastuzumab emtansine) 160mg Injection, the following steps should be taken: Contact Poison Control : Immediately reach out to your regional poison control center for guidance on managing the overdose. Monitor Symptoms : Patients should be closely monitored for any adverse effects, as overdose can lead to serious complications such as thrombocytopenia (low platelet count) and other severe reactions. No Antidote Available : Be aware that there is no known antidote for Kadcyla overdose, so management will focus on supportive care and monitoring. Seek Medical Attention : If symptoms develop or if there is any uncertainty regarding the overdose, seek medical attention promptly to ensure appropriate care.

Does Kedcyla 160mg Injection Affect Kidney Patients?

Yes, Kadcyla (ado-trastuzumab emtansine) 160mg Injection can be used in patients with kidney impairment, but there are important considerations: No dose adjustment is recommended for patients with mild or moderate renal impairment. Patients can generally receive Kadcyla without changes to the standard dosing regimen.

Can I Take Kedcyla 160mg Injection Before Driving?

No, It is advisable not to drive or operate machinery until you are sure that you can do so safely.

Back to products

Kedcyla 160mg Injection (Trastuzumab)

Kedcyla 160mg injection contains (transtuzumab) which is now available in Pakistan at Jasmeds. The price range of the Kedcyla 160mg injection is Rs 200,000 to Rs 400,000/-.

Product Description

Brand: Kedcyla
Form: Injection
Packet Size: 1 Injection
Active ingredient: (Trastuzumab Emtansine)
Manufacturer: Roche
Treatment: Breast Cancer

₨ 350,000

Add to wishlist

Description

How Does Kedcyla 160mg Injection Work?

Kedcyla 160mg Injection is a medication used to treat HER2-positive breast cancer.

It works by targeting and delivering a chemotherapy drug directly inside cancer cells.

HER2 Targeting: Kedcyla contains trastuzumab, an antibody that specifically targets the HER2 protein found on the surface of some breast cancer cells.

Chemotherapy Delivery: Trastuzumab is linked to a chemotherapy drug called emtansine. This combination allows Kedcyla to attach to HER2-positive cancer cells.

Cancer Cell Destruction: Once attached, Kedcyla releases emtansine inside the cancer cell. This chemotherapy drug then disrupts the cell’s internal structure, leading to cell death.

How Should You Take Kedcyla 160mg Injection?

Kadcyla 160mg Injection (ado-trastuzumab emtansine) is administered by a healthcare professional through intravenous (IV) infusion.

Kadcyla must be given in a hospital or clinical setting under the supervision of a trained healthcare professional.

Frequency: Kadcyla is administered once every three weeks as part of a treatment cycle.

First Dose: The first infusion is usually given over 90 minutes. During this time, your doctor will monitor you closely for any allergic or infusion-related reactions.

Subsequent Doses: If the first infusion is well-tolerated, future doses may be given over 30 minutes.

Additional Details

Uses of the Kedcyla 160mg Injection

Kadcyla 160mg Injection (ado-trastuzumab emtansine) is a targeted therapy used to treat HER2-positive breast cancer. It is prescribed for patients with metastatic breast cancer or early-stage breast cancer who have not responded to prior treatment with trastuzumab and a taxane chemotherapy.

Treatment of HER2-Positive Metastatic Breast Cancer: Kadcyla is effective in managing advanced HER2-positive breast cancer, particularly when prior therapies have failed. It helps to slow cancer progression and improve survival rates.

Post-Surgery Therapy: In early-stage HER2-positive breast cancer, Kadcyla is used as an adjuvant therapy to reduce the risk of cancer recurrence after surgery.

Targeted Action: Kadcyla specifically targets HER2-positive cancer cells, reducing side effects compared to traditional chemotherapy.

Recommended Dosage of Kedcyla 160mg Injection

The dosage of Kadcyla 160mg Injection (ado-trastuzumab emtansine) is determined based on a patient’s body weight and specific clinical condition.

Standard Dosage:

Dose Calculation: The recommended dose is 3.6 mg per kilogram of body weight.

Frequency: Kadcyla is administered once every three weeks (21-day cycle).

Route: The injection is given intravenously (IV) over a period of 30 to 90 minutes.

Initial and Subsequent Doses:

First Infusion: The first dose is infused over 90 minutes to monitor for any potential infusion-related reactions.

Following Doses: If the first infusion is well-tolerated, subsequent doses may be given over 30 minutes.

Warnings and Precautions of Kedcyla 160mg Injection

Kadcyla (ado-trastuzumab emtansine) requires careful administration under medical supervision due to its potential risks and side effects. Below are key warnings and precautions to consider:

Liver Toxicity:

Kadcyla can cause severe liver damage, including cases of liver failure. Monitor liver function tests (LFTs) regularly during treatment.

Patients with pre-existing liver conditions should be closely observed.

Heart Problems:

Kadcyla may lead to a reduction in heart function (cardiotoxicity), which can manifest as congestive heart failure (CHF) or decreased heart efficiency.

Ejection fraction monitoring is essential before and during treatment.

Infusion-Related Reactions:

Symptoms like fever, chills, or difficulty breathing may occur during or after the infusion.

First infusions require extended monitoring to detect and manage any reactions promptly.

Pulmonary Toxicity:

Kadcyla can cause severe lung problems, such as interstitial lung disease (ILD) or pneumonitis. Patients experiencing shortness of breath, cough, or chest pain should report these symptoms immediately.

Hemorrhagic Events:

Kadcyla has been associated with serious bleeding risks, especially in patients with low platelet counts or those on anticoagulants.

Regular platelet monitoring is recommended.

Neuropathy:

Kadcyla can cause or worsen peripheral neuropathy, resulting in numbness, tingling, or pain in the extremities.

Patients should report any new or worsening symptoms.

Pregnancy and Breastfeeding:

Kadcyla is not safe during pregnancy as it can harm the fetus. Women of childbearing potential should use effective contraception during treatment and for at least 7 months after the final dose.

Breastfeeding is not recommended during treatment with Kadcyla.

Severe Allergic Reactions: Rare but severe hypersensitivity reactions, including anaphylaxis, can occur. Immediate medical attention is required for symptoms like swelling, rash, or difficulty breathing.

Possible Side Effects of Kedcyla 160mg Injection

Kadcyla (ado-trastuzumab emtansine) can cause side effects ranging from mild to severe. It is essential to monitor for these effects during treatment and report any unusual symptoms to your healthcare provider.

Common Side Effects:

Fatigue – Feeling unusually tired or weak.

Nausea and Vomiting – Often manageable with anti-nausea medications.

Diarrhea – May require hydration and dietary adjustments.

Muscle or Joint Pain – Discomfort in the muscles or joints.

Constipation – Difficulty passing stools, which can be alleviated with dietary changes or laxatives.

Headache – Persistent headaches that may require over-the-counter medication.

Low Platelet Count (Thrombocytopenia) – Can increase the risk of bleeding or bruising.

Mild Hair Thinning or Loss – Temporary and typically improves after treatment.

Serious Side Effects:

Heart problems: Kedcyla can weaken the heart muscle, leading to heart failure.

Lung problems: Difficulty breathing or shortness of breath.

Infusion reactions: Allergic reactions during or shortly after the injection, such as fever, chills, rash, or difficulty breathing.

Bleeding: Increased risk of bleeding, including nosebleeds and bleeding gums.

Nerve damage: Tingling, numbness, or weakness in the hands or feet.

FAQ's

Customer Reviews

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Be the first to review “Kedcyla 160mg Injection (Trastuzumab)”

Related Products